TAXUS(R) coronary stent system cited by EuroIntervention for superiority in diabetic patients
17 Mai 2006 - 7:34PM
PR Newswire (US)
TAXUS benefits demonstrated in non-diabetic patient population
carry over into insulin-treated diabetic patients VANCOUVER, May 17
/PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ:
ANPI; TSX: ANP) along with its corporate partner Boston Scientific
Corporation ("BSC") has announced today that a peer-reviewed
medical journal affiliated with the Paris Course on
Revascularization called EuroIntervention, has released an
integrated analysis that further supports the strong performance of
the TAXUS(R) paclitaxel-eluting coronary stent system for the
treatment of coronary artery disease in diabetic patients. In the
analysis, diabetic patients who received a TAXUS stent system had
significantly lower rates of restenosis and repeat interventions
than those who received a bare-metal stent. The study appears in
the May edition of EuroIntervention, which is the official
scientific journal of the annual Paris Course on Revascularization.
The authors stated in the article that "The TAXUS benefit provided
for the high-risk diabetic population is in contrast to outcomes
with bare-metal stents, which are worse for diabetic patients. The
contrast between pro- stenotic forces with bare-metal stents and
anti-restenotic effects for diabetes receiving TAXUS suggests that
paclitaxel may also block restenotic pathways unique to the
diabetic milieu. For diabetic patients, especially the high-risk
insulin-treated group, this could dramatically improve clinical and
angiographic outcomes and offer a less-invasive approach to a
population with impaired wound healing." According to the authors,
a number of mechanistic factors may contribute to the observed
TAXUS stent benefit. They state that the unique mechanism of action
of paclitaxel, the drug used in TAXUS stents, supports their
conclusion of emerging evidence of the excellent efficiency of
TAXUS stents in insulin- dependent diabetics. The study is the
first to use an integrated analysis of randomized data to examine
aggregate results in a lower frequency but higher-risk diabetic
population. Four TAXUS clinical trials (TAXUS II, TAXUS IV, TAXUS V
and TAXUS VI) were included in the analysis, involving a total of
3,445 patients with coronary artery stenosis, 814 of whom had
diabetes. Assessments of lesion characteristics showed that
diabetic patients on average had more complex lesions than did
non-diabetic patients. While diabetes has been identified as a
strong predictor of restenosis after implantation of bare-metal
stents, the angiographic and clinical results of this integrated
analysis with similar outcomes independent of diabetic status
suggest a significant advantage of the TAXUS stent system in
diabetic patients, including the high risk insulin- treated subset.
The pooled clinical trial results at nine months reported a target
lesion revascularization (TLR) rate of 5.4 in non-diabetic patients
in the TAXUS group and a TLR rate of 5.8 percent in diabetic
patients (insulin-treateD) in the TAXUS group. BSC acquired
worldwide exclusive rights from Angiotech to use paclitaxel to coat
its coronary stent products and has co-exclusive rights to other
vascular and non-vascular products. About Angiotech
Pharmaceuticals, Inc. ------------------------------------- Founded
in 1992, Angiotech Pharmaceuticals, Inc. is a global specialty
pharmaceutical and medical device company, with 14 facilities in 6
countries and over 1,500 dedicated employees, that discovers,
develops and markets innovative, minimally invasive treatment
solutions for diseases or complications associated with medical
device implants, surgical interventions and acute injury. To find
out more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Statements contained in this press
release or in our other written or oral public communications that
are not based on historical or current fact, including without
limitation statements containing the words "believes," "may,"
"plans," "will," "estimate," "continue," "anticipates," "intends,"
"expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and constitute "forward-looking
information" within the meaning of applicable Canadian securities
laws. All such statements are made pursuant to the "safe harbor"
provisions of applicable securities legislation. Such
forward-looking statements are based on assumptions that involve
known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially
different from any future results, events or developments expressed
or implied by such forward-looking statements. Forward-looking
statements in this release include the statements regarding: the
applicability of the clinical data to patient. These statements are
subject to risks and uncertainties that could cause actual results
to differ materially from those projected. These risks and
uncertainties include, among others, the possibility of a change in
the regulatory environment in Europe and the risks and
uncertainties described in Angiotech's filings with the United
States Securities and Exchange Commission or the Canadian
securities regulators. The forward looking statements are also
based on a number of assumptions, including the applicability of
the clinical data to patient populations; that the study results
were collected and reported in accordance with the study protocol;
and that the study results have been accurately interpreted. Given
these uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. The Company does not
assume the obligation to update any forward-looking statements. FOR
ADDITIONAL INFORMATION: --------------------------- Analysts and
Investors: Janet Craig VP, Investor Relations and Corporate
Communications Angiotech Pharmaceuticals, Inc. (604) 221-6933
Media: Jodi Regts Manager, Corporate Communications Angiotech
Pharmaceuticals, Inc. (604) 221-7930 DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Analysts and Investors: Janet Craig,
VP, Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., (604) 221-6933; Media: Jodi Regts, Manager,
Corporate Communications, Angiotech Pharmaceuticals, Inc., (604)
221-7930
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024